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The etiology and pathogenesis of Parkinson’s disease (PD) is unknown, aging being the 
strongest risk factor for brain degeneration. Understanding PD pathogenesis and how 
aging increases the risk of disease would aid the development of therapies able to slow 
or prevent the progression of this neurodegenerative disorder. In this review we provide 
an overview of the most promising therapeutic targets and strategies to delay the loss of 
dopaminergic neurons observed both in PD and aging. Among them, handling alpha-
synuclein toxicity, enhancing proteasome and lysosome clearance, ameliorating 
mitochondrial disruptions and modifying the glial environment are so far the most 
promising candidates. These new and conventional drugs may present problems related 
to their labile nature and to the difficulties in reaching the brain. Thus, we highlight the 
latest types of drug delivery system (DDS)-based strategies for PD treatment, including 
DDS for local and systemic drug delivery. Finally, the ongoing challenges for the 
discovery of new targets and the opportunities for DDS-based therapies to improve and 
efficacious PD therapy will be discussed.  
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Parkinson`s disease (PD) is a neurodegenerative disorder characterized by the 
progressive loss of dopaminergic (DAergic) neurons of the substantia nigra pars 
compacta (SNpc), especially the DAergic neurons of the ventrolateral tier that project to 
the striatum [1]. The differential vulnerability of DAergic neurons to degeneration is 
still a matter of debate, but it seems to be related to increased sensitivity to 
mitochondrial dysfunction and changes in protein degradation [2–4]. The consequent 
decrease in striatal dopamine (DA) is correlated with motor impairment symptoms such 
as tremor, bradikynesia and rigidity. Non-motor symptoms such as sleep disorders or 
depression are also present during the disease, just as neuronal loss may occur in other 
brain regions. Lewy bodies (LBs) and neurites are intracellular inclusions that constitute 
the neuropathological hallmark of PD due to an abnormal protein aggregation of alpha-
synuclein (α-syn) predominantly [5].  
The etiology of PD is unknown although researchers believe that it may be caused by a 
combination of environmental and genetic factors, aging being the strongest risk factor 
[6,7]. The rate of progression of PD yields evidence of the natural loss of compensatory 
mechanisms associated with aging. In this way early-onset PD leads to a slower 
deterioration over time than late-onset PD [8]. The link or difference between aging and 
PD may be the intensity or acceleration of the neurological damage processes [9]. This 
imbalance of compensatory resources has led specialists to seek novel knowledge about 
the aging process. 
At present there is no cure for PD and current therapies are focused on DA replacement. 
Levodopa (L-DOPA) still remains the most effective drug for controlling PD symptoms 
[10,11]. However, as the disease progresses, many PD patients become severely 
disabled due to the appearance of non-DAergic symptoms, particularly in the advanced 
stage of the disease and to the occurrence of drug-induced side effects such as 
fluctuations [12]. In order to produce a marked benefit not only on motor symptoms but 
also on non-motor symptoms, non ergotic DA agonists such as pramipexol, ropinirol 
and rotigotine are now used [13]. Other adjuvant drugs block enzymes that break down 
L-DOPA/DA such as catechol-O-methyltransferase inhibitors and monoamine oxidase 
B (MAO-B) inhibitors inducing a longer duration of L-DOPA effect and decreasing 
fluctuations. Finally, the DA agonist apomorphine is used as a rescue therapy when 
unpredictable off periods appear along the day and the glutamate activity blocker 
amantadine is used as a potent antidyskinetic agent. Certain non-motor symptoms with a 
great impact on the quality of life do not respond to dopaminergic drugs and, 
consequently, new drugs that cover this gap are essential [14]. In addition, the 
development of a disease-modifying strategy has become a priority. In this regard, 
much has been learned in recent years about PD pathophysiology. Most of these 
discoveries have identified potential targets, which may lead to the development of 
novel PD therapies. Remarkably, most of the new drugs and potential therapies for PD 
are labile compounds that show short in vivo half-life and that come with the challenges 
of delivery to the central nervous system (CNS). Thus, innovative technologies able to 
5 
 
extend the length of the treatment, release drugs in a controlled manner or enhance brain 
drug delivery are the key to developing more effective treatments. In this regard, drug 
delivery systems (DDS) such as liposomes, microparticles (MPs), nanoparticles (NPs) 
or hydrogels, as well as conventional transdermal patches or subcutaneous implants, 
have shown great potential for improving the outcome of new and conventional 
therapies for PD [15]. The aim of this paper is to review novel therapeutic targets that 
may detain DAergic neurodegeneration observed both in PD and aging. Then, recent 
advances in the use of DDS for PD are discussed. Finally, the ongoing challenges for 
the discovery of new targets and the opportunities for DDS-based therapies for an 
improved and efficacious PD therapy will be discussed. 
 
2 METHODS 
Evaluation of the literature 
A MEDLINE search was conducted using the keywords aging, therapeutic targets, 
alpha-synuclein, mitochondrial disruptions, neuroinflammation, glia and Parkinson 
disease. For the section "Drug delivery systems approaches" the literature search, from 
2013 to 2015, included the keywords drug delivery systems, microparticles, 
nanoparticles, GDNF and Parkinson disease. All research papers and reviews with the 
mentioned contents were included in the review process. 
 
3 NEW THERAPEUTIC TARGETS 
Recent knowledge of the basic mechanisms and pathophysiology of PD might support 
the search for targets for treating this disease. In this section we will review the most 
promising therapeutic targets and strategies to detain the loss of DAergic neurons 
(Figure 1). 
3.1 Alpha-synuclein toxicity. Phosphorylation and aggregation  
This small peptide of 140 amino acids is the main LB component and it seems to be 
closely linked to PD pathogenesis [5] (Figure 1A). However, the role of α-syn on 
disease onset and progression is not totally understood. Physiologically, α-syn regulates 
synaptic activity by interacting with synaptic vesicles and promotes a snare complex 
assembly [16]. Interestingly, α-syn expression is increased with aging [8].  
The implication of synuclein in PD results from the identification of mutations in the 
SNCA gene (synuclein alpha non A4 component of amyloid precursor) in PD families. 
Duplication or triplication of SNCA (PARK4 locus) has also been implicated in PD, 
indicating that α-syn-wild type may trigger toxicity at high levels [7]. Point mutations in 
SNCA gene (PARK1 locus) affecting α-syn conformation are also associated with 
familial PD, thus targeting α-syn post translational modifications has also drawn the 
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attention of various authors to date and researchers have consequently focused on 
targeting α-syn for therapeutic intervention. 
In PD an aggregation balance may exist between α-syn oligomers, amyloid fibrils and 
LBs. This event might be a protective mechanism functioning like a garbage storing 
system, while the previous oligomer state might be the pathologic version. In this 
regard, phospho-α-syn has been reported to enhance oligomer and LB formation [17]. 
Phosphorylation of α-syn at serine 129 is characteristic of PD, polo-like kinase 2 
(PLK2) being the enzyme responsible for α-syn phosphorylation [18]. PLK2 has been 
reported to activate an antioxidant pathway to promote the survival of cells with 
mitochondrial dysfunction [19]. Furthermore, its gene is transcriptionally responsive to 
calcium and ROS (reactive oxygen species) signals. Additionally, PLK2 may 
phosphorylate PLK1 allowing bypass of DNA damage checkpoint cell cycle 
progression as well as participating in centrosome duplication [20]. On the grounds of a 
putative neurotoxic attribute, kinase activity modulators are being studied. Nevertheless, 
some controversial outcomes also support a neuroprotective role for PLK2. The 
difficulty in matching PLK2 implications could reside in the fact that this molecule is 
involved in several physiological pathways. Following this hypothesis, our group is at 
present working to validate this interesting target. 
Various pieces of evidence demonstrate a cell-to-cell transmission of α-syn as a prion-
like propagation process [21]. Although more studies are needed to confirm this event, 
immunotherapy focused on the clearance of this aggregates is now considered to be a 
new disease-modifiying therapy [22]. Immunotherapy is turning into an increasingly 
tangible reality and may offer promising neuroprotective drugs that could manage α-syn 
aggregation, spread or clearance. Recent studies in animal models of the disease have 
reported neuroprotection after passive or active immunization [4]. This approach may 
stop α-syn transcellular propagation but not intraneuronal inclusions, making it 
necessary to optimize intrabodies in order to detain intracellular α-syn as well [23].  
 
3.2 Proteasome and lysosome approach. 
The ubiquitin-proteasome system and the autophagic-lysosomal processes represent the 
two major degradation pathways for proteins including α-syn (Figure 1B). Both systems 
show a reduction in function and efficiency with age. There is evidence that soluble and 
oligomeric forms of α-syn are ubiquitinated and then degraded by the proteasome. Thus, 
impairment of ubiquitin proteasome system may lead to intracellular inclusions in PD 
[24]. Consequently, proteasome system activators should be investigated to design new 
drugs that facilitate α-syn clearance. In this regard, defective proteins are tagged via 
ubiquitination for proteasome selective destruction and the E3 ubiquitin protein ligase 
(parkin) mutation has been linked to familial PD [24]. 
The accumulation of the aged pigment lipofuscin as a lysosomal degradation product of 
damaged mitochondria indicates that macro autophagy is a neuroprotective mechanism 
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during aging [8]. Macro autophagy constitutes the unique mechanism to recycle entire 
organelles such as mitochondria [25]. Chaperone-mediated autophagy forms part of the 
third lysosome process in which a specific cytosolic protein–molecular chaperone 
(hsc70) binds to the lysosomal associated membrane receptor protein 2 (LAMP2A), 
before transporting inside the lysosome [26]. α-syn is a known substrate of chaperone 
mediated autophagy and it has been recently reported that α-syn overexpression is 
correlated with a decrease of LAMP-1, indicating an impairment of the phagocytic 
ability and generating a mitophagy dysfunction [27]. Dehay et al. proposed that 
glucosidase beta acid gene mutation that causes Gaucher´s disease and lysosomal 
ATPase transporter ATP13A2/PARK9 mutation may be related to an α-syn 
accumulation [28]. Murphy et al. have reported that LAMP2 protein isoforms are 
affected in different ways in PD [29] and Xilouri et al suggested that overexpressing 
LAMP2A, may decrease α-syn-induced neurodegeneration [26]. More investigations 
are needed to develop new molecules that enhance the lysosome-autophagy system 
improving α-syn degradation. Leucine-rich repeat kinase 2 (LRRK2) mutations 
represent a common genetic cause of PD and are implicated in various functions in 
which autophagy may be linked to PD [7]. Lee et al. demonstrated the neuroprotective 
potential of LRRK2 kinase inhibitors in LRRK2-induced neurodegeneration model 
[30]. 
 
3.3 Mitochondrial disruptions and oxidative stress. 
Mitochondrial dysfunction has been involved in the etiopathogenesis of PD (Figure 1C). 
Thus, mitochondrial-targeted therapies directed to up-regulate mitochondrial function 
have emerged as potential therapeutic targets for PD. Although PD is a consequent 
interplay of several factors, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 
other selective DA neurotoxins that inhibit mitochondrial complex currently used to 
create PD models support the mitochondrial impairment in PD [31]. PTEN-induced 
putative kinase 1 (PINK1) and E3 ubiquitin protein ligase (PARKIN) mutations involve 
different proteins and processes related to axonal transport, fusion/fission and 
mitophagy of damaged mitochondria [9] and have been implicated in familial PD. α-syn 
is also suggested to interact with membranes and organelles including mitochondria. In 
this sense, Bir et al. report that α-syn induces mitochondrial disruption in vitro [32]. 
Their study proposes that α-syn binds mitochondria, opening membrane permeability 
transition pores and triggering a potential transmembrane breakdown. Besides, LRRK2 
mutation, has recently been linked with mitochondrial degeneration [31].  
Mitochondria are a well-known source of oxidative stress. Oxidative stress plays an 
important role both in PD and aging (Figure 1C) According to this, and importantly, the 
protein deglycase DJ-1, a protector against oxidative stressors, is defective in both PD 
and aging [9]. Besides the fact that ROS and free radicals like H202 and OH
-
, are 
generated in the mitochondria, some perspectives support the view that the 
accumulation of cytosolic DA metabolites can be correlated with oxidative and nitrative 
damage to dopaminergic cells [8]. The DA transporter and the vesicular monoamine 
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transporter 2 may possess a defensive role in this regard, being in charge of withdrawal 
of the excess production of free radicals. In this regard, antioxidant replacement 
therapies play an important role in the search for novel drugs for neurodegenerative 
disorders of aging. On the other hand, Ca
2+
 dyshomeostasis has frequently been thought 
to be a consequence of cell damage in PD. The stress which arises between the 
endoplasmic reticule and the mitochondria to meet the requirement of sustained release 
of Ca
2+
 could contribute to LB formation and premature death of SNpc DA neurons 
[33]. Although this is not fully understood at present, use of approved Ca
2+
 channel 
antagonists may be assessed to attempt neuroprotection in PD. 
3.4 Glial environment and neuroinflammation 
Not only intracellular mechanisms but also the surrounding environment of the DAergic 
neurons have been described as contributing to disease progression and aging (Figure 
1D). Microglia have been described to like macrophages, secreting neuroinflammatory 
cytokines and leading cell degeneration [9]. Astrocytes support neuroprotection, 
changing their morphology or overexpressing glial fibrillary acidic protein. However, 
astrocyte activation has also been linked to most of the pathologies of the brain, 
including PD. Targeting the neuroinflammatory process may be a suitable strategy to 
cease PD progression. Umemura et al. designed a longitudinal retrospective analysis 
associating C-reactive protein with motor deterioration in parkinsonian patients showing 
that the subclinical elevation of this marker in plasma is linked to motor prognosis in 
PD [34]. Brundin et al. suggested that immunosuppression may reduce 
neurodegeneration, given that α-syn is an immune response inducer [22]. In this sense, 
calcineurin and tumor necrosis factor inhibitors were assayed achieving a cell survival 
enhancement and T cell infiltration decrease in vivo. Moreover, anti-inflammatory drugs 
like minocycline and non-steroidal anti-inflammatory agents are currently being 
investigated as potential neuroprotective therapies [3]. Finally, the glucagon-like 
peptide 1 receptor agonist exenatide, a drug used to treat type 2 diabetes, is currently 
being studied in clinical trials with parkinsonian patients [22]. 
The development of new drugs should be focused on activating proper neuroprotective 
and neurotrophic pathways as well as to trigger neurogenesis and gliogenesis. In this 
regard, it is useful to bear in mind the neurogenesis and gliogenesis provided by the 
subventricular zone as a compensatory mechanism and their possible involvement in PD 
and aging [9]. Neurotrophic factors such as glial cell-line derived neurotrophic factor 
(GDNF) could be of interest.  
 
4 DRUG DELIVERY SYSTEM APPROACHES 
To develop novel therapies from the strategies detailed above it is essential to devise 
suitable formulations to enhance and preserve their clinical potential. Many candidates 
and established drugs are labile molecules with short in vivo half-life that require a DDS 
to reach clinical applications. DDS are biodegradable or non-biodegradable 
formulations that offer improvements in the protection, absorption, penetration and 
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distribution of drugs (Figure 2). Innovative delivery systems are able to avoid first pass 
effect, allow sustained drug release over time, cross the blood brain barrier (BBB) and 
reduce toxic effects. Our previous work reviewed a detailed list of the DDS studies 
performed between 2008 and 2013 in the context of PD [15]. Here, we review studies 
published since 2013. 
4.1 DDS for local delivery 
DDS used for local treatment can be injected by stereotaxic surgery in a minimally 
invasive way in discrete precise and functional brain areas without damaging the 
surrounding tissue. Polymeric MPs or NPs may allow sustained release of drug over 
months, avoiding not only multiple administrations but also the complications related to 
this kind of intervention. 
DDS for dopamine delivery 
In order to restore DA content, a novel DA DDS was proposed encapsulating non 
autologous DA-secreting cells on a hybrid scaffold of alginate gel/3D framework [35]. 
Pores in alginate gel allow the transfer of oxygen, nutrients or hormones and block host 
patient antibodies. Although in vitro studies demonstrate a suitable DA release over 8 
weeks, appropriate in vivo studies are required to determine consistent clinical 
application.  
DDS for neurotrophic factor delivery 
One of the most exciting approaches for PD treatment is the use of the disease-
modifying growth factor GDNF. Our laboratory obtained interesting outcomes by 
administrating biodegradable GDNF-MPs in rat [36,37] and monkey model [38] of PD. 
In rats, GDNF-MPs achieved long-term neuroprotection and neurorestoration 
demonstrating that MP are an efficient vehicle for sustained neurotrophic factor delivery 
to the brain [36,37]. In addition, parkinsonian monkeys showed brain structural and 
functional recovery following local delivery of microencapsulated GDNF [38]. Herran 
et al. designed a combinatorial strategy by nanoencapsulating vascular endothelial 
growth factor (VEGF) and GDNF [39]. Motor function restoration and enhancement of 
DAergic neurons in the SN was observed after VEGF- and GDNF-loaded NP injection 
in the striatum of 6-hydroxydopamine (6-OHDA)-injured rats. Recently, Moloney et al. 
designed a fibrin-based scaffold for intracerebral delivery of GDNF overexpressing 
stem cells [40]. Thrombin and fibrinogen injection resulted in the in situ formation of 
fibrin in rat brains. Fibrin provided a substrate for the stem cells that were capable of 
secreting the neurotrophic factor. Fibrin biomaterial showed neither adverse effects on 
cell survival nor immunoreaction. Further studies are necessary to confirm the potential 
of this scaffold. In another study, Requejo et al. assessed the topographical distribution 
of morphological changes in the rat brain after the local injection of nanoencapsulated 
neurotrophic factors [41]. Synergistic combination of neurotrophic factors provided 
neuronal preservation and nigrostriatal axon restoration while proliferation assays 




4.2 DDS for systemic delivery 
Systemic delivery of certain DDS has the potential to cross the BBB and target specific 
brain regions. Coating DDS with surfactants such as polysorbate 80, dextran or 
polyethylene glycol (PEG) has been recently reviewed concerning neurodegenerative 
disorder applications [42]. Taking advantage of BBB endogenous receptors appears to 
be a suitable strategy to cross the BBB. With this aim, NPs were conjugated with 
transferrin, insulin, glutathione, LDL, angioPEP, hydroxibutiric acid or antibodies, and 
successful delivery of drugs across the BBB was achieved (revised in [43]). Currently, 
there is an emerging interest in the development of non-invasive methods to bypass the 
BBB and recent efforts have concentrated on the intranasal administration of DDS to 
the brain. 
DDS for dopamine agonist, protein inhibitor and peptide delivery 
A large number of studies have been performed using DDS to obtain sustained levels of 
active DA in the brain. For instance, Pahuja et al. designed DA-loaded poly(lactic-
coglycolic acid) (PLGA) NPs for intravenous delivery [44]. DA-PLGA-NPs crossed the 
BBB, reached the striatum and reversed functional deficits in 6-OHDA-lesioned rats. 
The constant slow release of DA allows the reduction of quinone adduct formation, DA 
autooxidation and other toxic events when compared to bulk DA administration. 
Gambaryan et al. developed PLGA-NPs for intranasal administration of L-DOPA [45]. 
In vivo studies confirmed a long-lasting effect of L-DOPA restoring the motor 
impairments compared to the free-drug. Di Gioia et al. developed intranasal DA 
delivery using glycol chitosan/sulfobytylether-b-cyclodextrin based NPs [46]. Ethylene 
glycol confers hydrophilic properties whereas chitosan-thiomer derivates give 
mucoadhesive attributes. The presence of the anionic sulfobytylether-b-cyclodextrin 
such as crosslinking agent was found to have a potential ability to stabilize DA. 
Mucociliary clearance turns out to be the most usual added difficulty when dealing with 
this type of administration. In order to reduce this inconvenience, substance P-loaded 
NPs modified with gelatin were proposed [47]. Gelatin confers a negative charge that 
may prolong NPs’ residence time in the mucociliar tract. In vivo studies also confirmed 
the neuroprotective role of substance P against 6-OHDA-induced apoptosis. Another 
nose to brain study that demonstrates enhanced brain targeting using DDS is that of 
Mittal et al., who prepared rasagiline-loaded chitosan glutamate NPs by ionic gelation 
[48]. Bioavailability assays determined a significant enhancement of this MAO inhibitor 
in the CNS. Similar results were obtained encapsulating DA agonist ropinirole in 
mucoadhesive NPs [49]. These studies demonstrated superiority over other delivery 
routes due to a prolonged and targeted brain effect. However, further in vivo studies 
should be accomplished to ensure the safety and efficacy of this route for chronic 
administration in PD patients. 
 
DDS for gene therapy 
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Viral gene delivery systems exhibit limitations and disadvantages including 
mutagenesis, carcinogenesis, and immune response. In order to avoid these issues 
viruses can be replaced by nanocarriers. In this sense, Liu et al. developed PEG-
polyethyleneimine NPs for α-syn siRNA delivery [50]. A significant decrease in 
endogenous α-syn was obtained by SNCA gene silencing in vitro. These complexes 
demonstrated high transfection and cytoprotective effect after inducing MPP+ cell 
apoptosis. Nevertheless, this promising gene therapy needs to be validated in vivo 
before definitive conclusions can be drawn. In another study, Huang et al. developed 
dendrigraft poly-lysine NPs loaded with hGDNF gene [51]. In order to cross the BBB, 
NPs were conjugated with PEG and AngioPEP, a small peptide able to interact with 
endogenous BBB receptors facilitating BBB crossing. Multiple intravenous 
administrations improved the recovery of rotenone induced parkinsonian rats. Recently, 
polyethylene imine grafted chitosan nanocarriers for GDNF gene delivery were assayed 
[52] demonstrating a high in vitro GDNF gene expression and confirming the 
biocompatibility of this approach. Therefore this application should be borne in mind to 
design future in vivo evaluations. 
 
DDS for neuroprotector and antioxidant delivery 
The lack of the natural antioxidants catalase, glutathione and superoxide dismutase, 
among others, in midbrain regions of parkinsonian patients is thought to be linked to PD 
pathogenesis. Thus, antioxidant approaches are being investigated as potential strategies 
to detain oxidative stress triggered by ROS. For instance, Da Rocha Lindner et al. 
reported an improved neuroprotective effect of resveratrol-loaded PLA NPs coated with 
polysorbate 80 compared with the free drug in vivo [53]. Haney et al. developed 
catalase loaded exosomes [54]. These non-toxic nanosized vesicles (100–200 nm) with 
immune privilege status are secreted by cells for long distance intercellular 
communications. Tetraspanins and integrins on exosomes surface yield BBB crossing 
and internalization via endocytosis. In vivo studies demonstrate a reduction of brain 
inflammation after intranasal and intravenous administration. This innovative approach 
deserves further investigation with a view to clinical CNS delivery. 
Esteves et al. demonstrated the neuroprotective effect of nanoencapsulated retinoic acid 
on a MPTP-mouse model of PD. Polymeric NPs were prepared by electrostatic 
interaction of polyethylenimine complexed with retinoic acid and dextran sulfate [55]. 
Retinoic acid NPs may induce the expression of mRNA and the protein transcription 
factors Nurr1 and Pitx3, responsible for DA neuronal survival and development. 
However, retinoic acid controlled release must be assayed and clarified sufficiently, for 
obvious safety reasons. 
 
DDS for neurotrophic factor delivery 
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A new nose to brain non-invasive delivery of neurotrophic factor was developed by 
Zhao et al. combining the advantages of polymeric NPs, fat emulsions, and liposomes 
[56]. A functional recovery in hemiparkinsonian rats was observed by encapsulating 
basic fibroblast growth factor in phospholipid-based gelatin NPs. The protein level of 
this growth factor in different regions of rat brain suggested that exogenous 
neurotrophic factor could reach the olfactory bulb and striatum via nasal epithelium 
without damaging the mucous membrane. 
 
5 CONCLUDING REMARKS  
PD pathogenesis still remains unclear and the molecular basis operating in the pathways 
of DAergic cell death are unknown. Moreover, aging acts on many cellular processes 
influencing PD progression. In order to modify the progression of the disease, 
understanding the exact relationship between age and PD may create opportunities for 
intervention. Animal models are the best way to understand PD pathogenesis and also to 
solve some questions related to disease, for example the role of LBs or the vulnerability 
of certain DAergic neurons to neurodegeneration. However, current animal models do 
not recapitulate all the features that take place in the human PD brain. Consequently, 
animal models that resemble the disease features in a more realistic way are required. 
In addition, understanding the underlying mechanisms of PD etiology will be the key to 
identifying molecular targets for innovative treatments. In this sense, targeting α-syn for 
therapeutic intervention has been extensively investigated. However, since the exact 
role of α-syn is not totally understood, care must be taken when decreasing α-syn 
nonspecifically. Perhaps it would be better to up-regulate the intrinsic clearance 
mechanisms of toxic α-syn, like the lysosomal system.  
Concerning current PD treatments, most of them are aimed at addressing motor 
symptoms, but there is no therapy focused on modifying the course of the disease. In 
addition, certain non-motor symptoms with a great impact on the quality of life in PD 
patients do not always respond to DAergic drugs. Thus, there is an urgent need to 
develop both symptomatic and disease-modifying therapies. Most probably, a 
combination of drugs with different mechanisms of action may be necessary, probably 
all of them combined within a DDS. As demonstrated in this review, the use of DDS 
presents enormous benefits for drug administration, and may ultimately result in better 
therapies for PD. Advances in DDS use have opened up unprecedented possibilities 
given their ability to enhance drug potential while reducing the side effects. However, 
additional work is required before any of these promising strategies will become 
available in clinical practice bringing major benefits to PD patients.  
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Figure 1: New therapeutic targets for PD treatment including emerging 
pharmacological disease modifying strategies to detain dopamine neuron death 
(green). (A) Alpha-synuclein (α-syn) aggregation and phosphorylation. α-syn natural 
monomer or tetramer conformation and pathologic aggregation equilibrium. Passive or 
active immunization or phosphorylation inhibition may detain oligomerization and 
fibrillation as well as transcellular propagation. (B) Proteosome lysosome approach. α-
syn proteasome and lysosome defective cleareance. α-syn is a substrate of cytosolic 
chaperone protein that binds LAMP2A allowing chaperone mediated autophagy. α-syn 
is ubiquitinated by E3 ubiquitin protein ligase for proteosome recognition and 
degradation. (C) Mitochondrial disruptions and oxidative stress. Defective axonal 
transport or fussion/fission processes, mitophagy impairment and α-syn mitochondrial 
membrane interaction among others may lead to mitochondrial disruptions. Calcium 
dyshomeostasis between endoplasmic reticule and mitochondria or free radical 
accumulation triggers neuronal degeneration. (D) Neuroinflammation and glial 
environment. Microglia secrete cytokines generating a neuroinflammatory environment. 
Astrocyte release chemokines to regulate glial environment and secrete antioxidants as 
well as neurotrophic factors to promote gliogenesis and neuronal reparation.  
 
Figure 2: A) Surface-modified NP. Drug is embedded in a degradable or non-
degradable matrix allowing controlled release and drug protection. (B) Image of 
transmission electronic microscope (TEM) showing polymeric nanoparticles under 
investigation for PD treatment. 
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